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Abstract: Background: Many studies have suggested that the regular use of non-steroidal anti-inflammatory drugs 
(NSAIDs), including aspirin, has a protective effect and survival benefit on colorectal cancer (CRC). However, recent 
data suggest that CRCs have different responses to NSAIDs depending on the timing of NSAID initiation, duration 
of NSAID use, and molecular characteristics of the tumor. The aim of this study was to evaluate the effect of long-
term prediagnostic aspirin use on the prognosis of stage III CRC. Methods: From 2007 to 2009, patients who were 
diagnosed with stage III CRC were recruited, and their medical records were retrospectively analyzed. Patients were 
divided into prediagnostic aspirin users (who used aspirin for more than three months continuously before CRC 
diagnosis) and non-users (who did not use of aspirin and NSAIDs). The two groups were compared in terms of recur-
rence, cancer-specific mortality, disease-free survival (DFS), and cancer-specific survival. In an experimental study, 
three CRC cell lines (Caco2, SW480, and DLD-1) were pretreated with aspirin (1 mM) for four days or 28 days to 
make aspirin-resistant cells, treated with 5-fluorouracil (5-FU; 2 µM), and apoptosis was measured with flow cytom-
etry using Annexin-V and propidium iodide double staining. Results: Compared with the aspirin non-users (N=565), 
the prediagnostic aspirin users (N=121) were not different in terms of baseline characteristics including tumor char-
acteristics, except for comorbidities and diabetes medication and statin use, which were higher in the prediagnostic 
aspirin users. Recurrence and cancer-specific mortality in stage III CRC were significantly higher in prediagnostic 
aspirin users than non-users (46.7% vs. 32.3%, P=0.003 and 32.2% vs. 19.8%, P=0.003, respectively). Survival 
analysis using Cox proportional hazards modeling demonstrated that DFS was significantly worse in prediagnostic 
aspirin users than non-users (HR, 1.525 (1.018-2.286); P=0.041). In cell line experiments, long-term aspirin pre-
treatment induced an increase in 5-FU-induced apoptosis in SW480 cells compared with control treatment without 
aspirin pretreatment. However, Caco2 cells showed a significant decrease of apoptosis in the same experiments 
and no change in DLD1 cells. Conclusion: Prediagnostic long-term aspirin use in stage III CRC could be a negative 
prognostic factor depending on the characteristics of the CRC. 
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Introduction
Colorectal cancer (CRC) is one of the most com-
mon malignancies in both Asian and Western 
countries [1, 2]. In proportion to the increasing 
CRC incidence, the health care costs of patients 
with CRC are also increasingly accelerating due 
to the development of new treatment regimens. 
To reduce cancer recurrence and improve sur-
vival in patients with CRC, the use of tumor-
suppressing substances as adjuncts to conven-
tional chemotherapy has been a focus of inves-
tigation. The results suggest that these sub-
stances could potentially be used for the pre-
vention of recurrence. Many observational and 
randomized, controlled studies have suggested 
a protective effect of regular aspirin use against 
colorectal neoplasms [3-6]. Favorable out-
comes associated with aspirin use after the 
diagnosis of colorectal cancer suggest that 
aspirin may be a promising agent for adjuvant 
therapy [7-10]. Therefore, in this respect, non-
steroidal anti-inflammatory drugs (NSAIDs) 
including aspirin are inexpensive and well-toler-
ated drugs that may prove to be an effective 
agent in preventing CRC recurrence, although 
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this benefit should be estimated relative to side 
effects including gastrointestinal and hemor-
rhagic toxicity.
However, in the studies where the effects of 
NSAIDs or aspirin use on survival after colorec-
tal cancer diagnosis were evaluated, a greater 
reduction in colorectal cancer mortality was 
found in patients who used aspirin only after 
diagnosis [7, 10, 11]. Furthermore, a large pro-
spective cohort study about aspirin use and 
survival in non-advanced colorectal cancer 
showed that compared with non-users, partici-
pants who regularly used aspirin after diagno-
sis had a better prognosis [9, 12]. In contrast to 
aspirin use after diagnosis, long-term use of 
aspirin or NSAID prior to cancer diagnosis did 
not show consistent results in cancer-specific 
or overall survival [7, 11]. 
Through various molecular mechanisms such 
as inhibition of cyclooxygenase and the NF-κB 
signaling pathway and activation of apoptotic 
signals [13], NSAID use is known to correlate 
with prevention of CRC development. However, 
nothing is known about the behavior of CRC 
that has developed under long-term NSAID 
exposure by evading the tumor suppressive 
effect of NSAIDs. 
We hypothesized that CRC development, even 
in long-term NSAID users, might induce 
different tumor characteristics such as poor 
response to adjuvant chemotherapy and more 
recurrence compared with CRC in NSAID 
non-users.
Therefore, we suggest the possibility that 
tumors that initially developed despite long-
term exposure to aspirin may be less suscepti-
ble to any potential effects of adjuvant chemo-
therapy on tumor recurrence after surgery due 
to changed tumor biology, and they may have a 
different prognosis compared to tumors that 
have never been exposed to aspirin. However, 
up to now, there has been little data about 
prognosis in prediagnostic aspirin users com-
paring to aspirin non-users, particularly in the 
context of stage III or IV CRC. 
In focusing on these points to maximize the 
effect on tumor recurrence, we investigated the 
effect of long-term prediagnostic aspirin-use on 
tumor recurrence in stage III CRC patients and 
demonstrated the possible effects of prediag-
nostic long-term aspirin use in an in vitro exper-
imental model. 
Materials and methods
Patients
From January 2007 to December 2009, 925 
patients who were diagnosed with stage III CRC 
at Severance Hospital were recruited. A total of 
239 cases were excluded due to: 1) age less 
than 20 years at diagnosis (N=2), 2) loss to fol-
low-up within one month without any tumor 
response evaluation at Severance Hospital 
(N=98), 3) coexistence of other malignancies 
within five years prior to diagnosis of CRC 
(N=55), 4) pathology other than adenocarcino-
ma (N=3), 5) taking NSAIDs only after diagnosis 
with CRC (N=78), and 6) use of non-selective 
NSAIDs or COX-2 selective NSAIDs only (N=3). 
Ultimately, a total of 686 patients were includ-
ed in the study. They were divided into two 
groups: prediagnostic aspirin users (N=121) 
who used aspirin for more than three months 
continuously prior to CRC diagnosis and non-
users (N=565) who did not use aspirin, non-
selective NSAIDs, or COX-2 selective NSAIDs.
Study design
A retrospective study was conducted based on 
medical records. Patient-related factors such 
as age, sex, body mass index (BMI), smoking 
history, alcohol history, family history, Eastern 
Cooperative Oncology Group (ECOG) perfor-
mance status, and comorbidities were investi-
gated. Also, tumor-related factors such as T 
stage, N stage, primary site (colon or rectum), 
initial carcinoembryonic antigen (CEA) level, 
pathology (adenocarcinoma or mucinous malig-
nancy), pathologic differentiation, and micro-
satellite instability (MSI) were investigated. In 
addition, first-course treatment and type of 
chemotherapy were surveyed. Aspirin-related 
factors such as type, dose, duration of aspirin 
usage, and timing in relation to colorectal 
cancer diagnosis were investigated, and other 
medications (metformin, thiazolidinediones, 
insulin, and statins) that may affect colorectal 
cancer prognosis were also surveyed. 
For evaluation of the prognosis of colorectal 
cancer, we used recurrence rate, cancer-specif-
ic mortality rate, disease-free survival (DFS), 
and cancer-specific survival.
In vitro cell line experiments
Cell lines and aspirin treatment: The human 
CRC cell lines (Caco-2, SW480, and DLD1) 
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were purchased from American Type Culture 
Collection (ATCC; Manassas, VA). Cells were 
cultured in Dulbecco’s modified Eagle’s medi-
um (DMEM) with 10% fetal bovine serum 
(Hyclone, Logan, UT), 100 units/ml penicillin, 
100 mg/ml streptomycin (Invitrogen, Carlsbad, 
CA), and 2 mM L-glutamine (Life Technologies, 
Carlsbad, CA). All cells were maintained in a 5% 
CO2 incubator at 37°C. The media were changed 
every two days, and the cells were separated 
via trypsinization using trypsin/EDTA when they 
reached subconfluence. 
Aspirin was purchased from Sigma (St. Louis, 
MO), dissolved in dimethyl sulfoxide (DMSO) as 
a 1 M stock solution, and stored at 4°C in the 
dark. The stock solution was diluted to the 
appropriate concentrations with medium imme-
diately before use. The concentration of aspirin 
(1 mM) was chosen based on the intracellular 
concentrations achieved after oral administra-
tion [13]. Each cell line was exposed to 1 mM of 
aspirin for 48 h, and the medium with 1 mM 
aspirin was changed regularly for 8 days or 28 
days. 
Measurement of 5-FU-induced apoptosis using 
flow cytometric analysis: Three CRC cell lines 
(Caco2, SW480 and DLD-1) were pretreated 
with aspirin (1 mM) for 8 days or 28 days, and 
then treated with 5-FU (2 µM) for 24 hours. 
Apoptosis was measured by flow cytometry 
using Annexin-V and propidium iodide double 
staining. Annexin V staining was done using an 
Annexin V-FITC Apoptosis kit (BD Pharmingen, 
Franklin Lakes, NJ, USA), according to the man-
ufacturer’s protocol. Annexin V- and propidium 
iodide-positive cells were measured at a fluo-
Table 1. Comparison of baseline characteristics between aspirin non-users and prediagnostic aspirin 
users with stage III colorectal cancer
Aspirin non-users 
N=565
Prediagnostic aspirin users
N=121
P value
Age (mean ± SD, years) 57.55 ± 11.75 66.30 ± 9.26 <0.001
Sex, N (%)
    M/F 263 (40.8) 0.070 0.070
BMI (≥25 kg/m2) 134 (23.7) 32 (26.4) 0.525
Smoker, N (%) 
    Never/former/current 347 (61.2)/107 (18.9)/112 (19.8) 69 (57.0)/31 (25.6)/21 (17.4) 0.244
Alcohol, N (%)
    Never/<1 bottle/day/>1 bottle/day 307 (54.3)/213 (37.7)/45 (8.0) 62 (51.2)/50 (41.3)/9 (7.4) 0.758
Colorectal ca. familial Hx, N (%) 42 (7.4) 6 (5.0) 0.333
ECOG, N (%) 
    0-1/2 118 (97.6)/3 (2.5) 118 (97.6)/3 (2.5) 0.206
Comorbidity, N (%)
    HTN 142 (25.1) 103 (85.1) <0.001
    DM 79 (13.8) 45 (37.2) <0.001
    CAD 1 (0.2) 23 (19.0) <0.001
    CVA 9 (1.6) 20 (16.5) <0.001
    Renal failure 10 (1.8) 7 (5.8) 0.019
    Hepatitis 29 (5.1) 5 (4.1) 0.643
    Hx of TBc 42 (7.4) 10 (8.3) 0.754
Aspirin use duration (mean ± SD, months) - 83.26 ± 56.24
Prediagnostic duration (mean ± SD, months) - 61.66 ± 48.12
Post-diagnostic duration (mean ± SD, months) - 21.60 ± 26.18
Medication, N (%)
    Metformin 43(7.6) 24 (19.8) <0.001
    TZD 4 (0.7) 6 (5.0) 0.003
    Insulin 4 (0.7) 7 (5.8) 0.001
    Statin 28 (5.0) 27 (22.3) <0.001
Variables are expressed as mean ± SD or n (%). Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; BMI, body mass index; SD, stan-
dard deviation; Hx, medical history; ECOG, eastern cooperative oncology group; HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery 
disease; CVA, cerebrovascular accident; TBc, tuberculosis; TZD, thiazolidinediones.
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Table 2. Comparison of tumor characteristics and treatment modality between aspirin non-users and prediagnostic aspirin users with stage III 
colorectal cancer
Aspirin non-users
N=565
Prediagnostic aspirin users
N=121
P value
Initial stage, N (%) 0.727
    Stage IIIA 52 (9.2) 11 (8.9)
    Stage IIIB 376 (66.4) 86 (69.9)
    Stage IIIC 138 (24.4) 26 (21.1)
T stage, N (%) 0.862
    T1/T2/T3/T4a/T4b 16 (2.8)/42 (7.4)/386 (68.3)/119 (21.1)/2 (0.4) 5 (4.1)/9 (7.4)/82 (67.8) /25 (20.7)/0 (0.0)
N stage, N (%) 0.903
    N1a/N1b/N1c/N2a/N2b 224 (39.6)/139 (24.6)/1 (0.2)/127 (22.5)/74 (13.1) 39 (32.2)/46 (38.0)/0 (0.0)/17 (14.0)/19 (15.7)
Site, N (%) 0.350
    Proximal colon/Distal colon/Rectum 113 (20.0)/194 (34.3)/258 (45.7) 31 (25.6)/41 (33.9)/49 (40.5)
Initial CEA (mean ± SD, g/) 12.76 ± 69.70 7.14 ± 13.26 0.383
Pathology, N (%)
    Adenocarcinoma/mucous 540 (95.6)/25 (4.4) 117 (96.7)/4 (3.3) 0.579
Histologic differentiation, N (%) (N=612, N=118) 0.294
    WD/MD/PD 49 (9.1)/458 (85.4)/29 (5.4) 16 (13.8)/93 (80.2)/7 (6.0)
MSI, N (%) (N=338, N=14) 0.106
    MSS/MSI-L/MSI-H 266 (89.9)/20 (6.8)/10 (3.4) 64 (92.8)/1 (1.4)/4 (5.8) 0.322
Surgical therapy, N (%) 564 (99.8) 120 (99.2)
RTx, N (%) 0.253
    None/neoCCRTx/adjuCCRTx/RTx 379 (67.1)/86 (15.2)/99 (17.5)/1 (0.2) 90 (74.4)/13 (10.7)/17 (14.0)/1(0.8)
CTx, N (%) 0.044
    None/adju/neo 20 (3.5)/471 (83.4)/74 (13.1) 9 (7.4)/103 (85.1)/9 (7.4)
Type of CTx, N (%) 0.293
    FOLFOX/FL/Xeloda/TS-1/other 297 (54.5)/189 (34.7)/43 (7.9)/7 (1.3)/9 (1.7) 65 (58.0)/31 (27.2)/13 (11.6)/1 (0.9)/2 (1.8)
Variables are expressed as mean ± SD or n (%). Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; CEA, carcinoembryonic antigen; WD, well differentiated; MD, moder-
ately differentiated; PD, poorly differentiated; MSI, microsatellite instability; MSS, microsatellite stable; MSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; RTx, 
radiotherapy; CCRTx, concurrent chemoradiation therapy; CTx, chemotherapy; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; FL, fluorouracil and leucovorin; TS-1, oral fluoropyrimi-
dine.
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rescence intensity of 1×104 cells using the 
FACSCalibur system (Becton & Dickinson, San 
Jose, CA, USA). For evaluation of apoptosis, 
FITC Annexin V-positive and PI-negative (early 
apoptosis) cells and FITC Annexin V- and 
PI-positive (end stage apoptosis and death) 
cells were calculated together.
prediagnostic aspirin users than non-users 
(66.34 ± 9.20 vs. 57.95 ± 11.62, P<0.001). 
Comparing the two groups, other patient-relat-
ed factors (sex, BMI, smoking history, alcohol 
history, family history of CRC, ECOG perfor-
mance status, and comorbidities) also were 
not significantly different. However, comorbidity 
Figure 1. Disease-free survival (DFS) and cancer-specific survival of prediagnos-
tic aspirin users and non-users among patients with stage III colorectal cancer. 
A. DFS was significantly shorter in prediagnostic aspirin users than in non-users 
(P=0.002). B. Cancer-specific survival was also decreased in the prediagnostic 
aspirin user group compared with the non-user group (P=0.003). Kaplan-Meier 
curves were used to stratify prediagnostic aspirin use. 
Statistical analysis
Continuous variables were 
expressed as mean ± 
standard deviation (SD). 
Baseline characteristics of 
the aspirin non-users and 
prediagnostic aspirin users 
were compared by Stu- 
dent’s t-test for continuous 
variables and Chi-square 
test or Fisher’s exact test 
for categorical variables. 
The logistic regression me- 
thod was used for multivari-
ate analysis. The Kaplan-
Meier method was used to 
estimate the distribution of 
the time from diagnosis to 
DFS and cancer-specific 
survival according to wheth-
er or not aspirin was used. 
Cox proportional hazards 
modeling was used to con-
trol for multiple risk factors 
that have been shown to 
influence colorectal cancer 
prognosis to compute 95% 
confidence intervals (CIs). 
Results were considered to 
be statistically significant 
with P<0.05. All statistical 
analyses were performed 
using SPSS version 18.0 
(SPSS Inc., Chicago, IL, 
USA). 
Results
Baseline characteristics 
The baseline characteris-
tics of the aspirin non-users 
and the prediagnostic aspi-
rin users are summarized 
in Table 1. The mean age 
was significantly higher in 
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prevalence, including hypertension, diabetes 
mellitus, coronary artery disease, cerebrovas-
cular accident, and renal failure was higher in 
prediagnostic aspirin users than in non-users 
(P<0.001, P<0.001, P<0.001, P<0.001, and 
P=0.020, respectively). The baseline medica-
tions, including metformin, TZD, insulin, and 
statins, were used more frequently in prediag-
nostic aspirin users due to preexisting underly-
ing diseases (P<0.001, P=0.003, P=0.001, 
and P<0.001, respectively). The average dura-
tion of aspirin use in the prediagnostic aspirin 
users was 82.74 ± 56.02 months.
The tumor characteristics between the two 
groups were not significantly different, includ-
ing initial stages, which were determined based 
on AJCC (American Joint Committee on Cancer) 
7th edition, primary site, pathology, pathologic 
differentiation, CEA at diagnosis, and MSI sta-
tus. The treatment modality among the three 
groups was also not significantly different in 
terms of surgery, radiation therapy, and chemo-
therapy (Table 2).
Prognostic differences between prediagnos-
tic aspirin users and non-users with stage III 
colorectal cancer
Long-term prediagnostic aspirin use affected 
the prognosis of stage III colorectal cancer in 
both the univariate analysis and multivariate 
analysis. Between the two groups, the prediag-
nostic aspirin user group showed a higher rate 
of recurrence and cancer-specific mortality 
than non-users (recurrence: 46.7% vs. 32.3%, 
P=0.003 and cancer-specific mortality: 32.2% 
vs. 19.8%, P=0.003). The prediagnostic aspirin 
user group had a shorter DFS in the univariate 
analysis than the non-user group (33.32 ± 
25.54 months vs. 40.46 ± 23.90 months, 
P=0.006). Also, the prediagnostic aspirin user 
group had a shorter overall survival than the 
non-user group, although it was not statistically 
Table 3. Cox regression analysis of factors related with recurrence and cancer-specific mortality 
Disease-free survival Cancer-specific survival
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (mean ± SD, years) - 0.591 - 0.073
Sex - 0.541 - 0.590
Comorbidity HTN - 0.302 - 0.213
DM - 0.106 - 0.436
CAD - 0.366 - 0.784
CVA - 0.561 - 0.251
Renal failure - 0.765 - 0.574
Pre-diagnosis aspirin use (vs. non-use) 1.525 (1.018-2.286) 0.041 - 0.170
Metformin - 0.781 - 0.478
TZD - 0.326 - 0.875
Insulin - 0.722 - 0.067
Statin (vs. non-user) 0.488 (0.281-0.848) 0.011 0.480 (0.239-0.966) 0.040
Initial stage 
    IIIB (vs. IIIA) 3.248 (1.498-7.040) 0.003 - 0.112
    IIIC (vs. IIIA) 6.372 (2.890-14.051) <0.001 6.875 (2.460-19.216) <0.001
Pathologic differentiation
    MD (vs. WD) - 0.114 - 0.273
    PD (vs. WD) 3.574 (1.758-7.265) <0.001 6.006 (2.469-14.607) <0.001
Cancer primary site 
    Rectum (vs. colon) 1.482 (1.122-1.958) 0.006 - 0.616
    CTx (vs. non-CTx) 0.462 (0.232-0.921) 0.028 - 0.064
Abbreviations: CI, confidence interval; HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; CVA, cerebro-
vascular accident; TZD, thiazolidinediones; WD, well differentiated; PD, poorly differentiated; CTx, chemotherapy. Cox propor-
tional hazard model adjusted for age, sex, comorbidity, pre-diagnosis aspirin use, medication, cancer site, initial stage and 
pathological differentiation.
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Figure 2. 5-FU-induced apoptosis after long-term pretreatment of aspirin in colon cancer cell lines. Aspirin (1 mM) was pretreated for 8 or 28 days in three CRC cell 
lines (Caco2, SW480, and DLD-1). Then, after 24 hr of treatment with 5FU (2 µM), apoptosis was measured by flow cytometry using Annexin-V and propidium iodide 
double staining. While aspirin-pretreated SW480 cells showed an increase in 5-FU-induced apoptosis, Caco2 cells showed a significant decrease in apoptosis in 
aspirin-pretreated cells in a pretreatment duration-dependent manner, and DLD1 cells did not show any significant change in the same set of experiments. Graphs 
represent the combined percentage of early (UR) and late (LR) apoptosis relative to all cells. Data are expressed as means of triplicate determinations (mean ± 
standard error) and are representative of three independent experiments. *P<0.05.
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significant (48.56 ± 20.01 months vs. 52.40 ± 
17.51 months, P=0.052).
In the survival analysis, prediagnostic aspirin 
use affected the prognosis of stage III colorec-
tal cancer in both the univariate analysis and 
multivariate analysis (Figure 1 and Table 3). In 
order to identify the effect of aspirin on DFS 
and cancer-specific survival, we used Kaplan-
Meier curves stratified by aspirin use or the 
lack of aspirin use. DFS and cancer-specific 
survival were significantly decreased in predi-
agnostic aspirin-users than in non-users 
[P=0.002 and P=0.003, respectively; Figure 
1A and 1B]. In addition, using Cox proportional 
hazards modeling adjusted for age, sex, comor-
bidity, medication, chemotherapy, cancer site, 
initial stage, and pathologic differentiation, 
DFS was significantly decreased in prediagnos-
tic aspirin users than non-users [HR, 1.525 
(1.018-2.286); P=0.041]. Also, statin use, ini-
tial stage IIIB (vs. IIIA), initial stage IIIC (vs. IIIA), 
PD pathologic differentiation (vs. well differenti-
ated), primary cancer site, and chemotherapy-
affected CRC DFS on the multivariate analysis 
[HR=0.488 (0.281-0.848), P=0.011; HR=3.248 
(1.498-7.040), P=0.003; HR=6.372 (2.890-
14.051), P<0.001; HR=3.574 (1.758-7.265), 
P<0.001; HR=1.482 (1.122-1.958), P=0.006; 
and HR=0.462 (0.232-0.921), P=0.028, 
respectively]. However, cancer-specific survival 
was not significantly different between the pre-
diagnostic aspirin users and the non-users on 
multivariate analysis (Table 3). 
Cell line-specific differences in 5FU-induced 
apoptosis in long-term aspirin-pretreated CRC 
cells 
Figure 2 shows cell line-specific differences in 
5FU-induced apoptosis measured with flow 
cytometry in Caco2, SW480, and DLD-1 cell 
lines. Three CRC cell lines (Caco2, SW480, and 
DLD-1) were pretreated with aspirin (1 mM) for 
8 or 28 days each, and then were treated with 
5-FU (2 µM). After 24 hr of 5FU treatment, 
apoptosis was measured by flow cytometry 
using Annexin-V and propidium iodide double 
staining. While aspirin-pretreated SW480 
showed an increase in 5-FU-induced apoptosis, 
compared with the control without pretreat-
ment of aspirin, Caco2 cells showed a signifi-
cant decrease in apoptosis in a pretreatment 
duration-dependent manner, and DLD1 cells 
did not show any significant change in the same 
set of experiments (Figure 2).
Discussion
In most studies that have demonstrated the 
effect of NSAIDs on CRC survival, they present-
ed an overall effect on CRC. However, we 
focused on the recurrence of CRC, especially to 
show a possible difference in the behavior of 
CRC with prediagnostic long-term NSAID expo-
sure, thereby reducing the effect of post-opera-
tive adjuvant chemotherapy, and thus finally 
leading to a difference in tumor recurrence. 
Therefore, we identified patients with stage III 
CRC and focused on their recurrence of CRC. As 
a result, we found that long-term use of aspirin 
before the diagnosis of stage III colorectal can-
cer was associated with a poor outcome in 
terms of recurrence and DFS.
Many reports have shown that NSAIDs, includ-
ing aspirin, extend the survival of patients with 
colorectal cancer [7, 9, 10, 14], but these stud-
ies showed a benefit mostly in post-diagnostic 
NSAID users, not in those who were taking 
NSAIDs regularly prior to diagnosis. Meanwhile, 
a recent large-scale study recently showed that 
the regular use of NSAIDs prior to diagnosis is 
associated with improved colorectal cancer 
survival, particularly among cases diagnosed 
with proximal disease [15]. However, recent 
meta-analysis data showed no prognostic ben-
efit of prediagnostic NSAID use in CRC [16]. 
The beneficial effects of NSAIDs cannot be gen-
eralized in all patients, and there have been 
some studies of the limited effects of NSAIDs. 
These studies have suggested that only CRC 
patients with specific factors such as COX-2 
overexpression or specific mutations in genes 
like SMAD7 and PIK3CA would benefit from 
NSAID use [7, 17, 18]. Chan, et al. reported 
that, among patients with colorectal cancer 
participating in a large cohort study, aspirin 
users had a 29% lower cancer-specific mortali-
ty and a 21% lower overall mortality than non-
users. The reduction in mortality was even 
greater among patients who initiated aspirin 
use after cancer diagnosis than among those 
who used it before, and the benefit was limited 
to those with tumors that overexpressed COX-2 
[7]. Another study showed that regular use of 
aspirin after diagnosis was associated with 
superior CRC-specific survival in patients with 
mutated PIK3CA CRC, but not in patients with 
wild-type PIK3CA, proposing it as a predictive 
molecular biomarker for adjuvant aspirin thera-
py [17]. 
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Moreover, a large case-control study undertak-
en to extend the Genome-wide Association 
Study (GWAS) findings noted a statistically sig-
nificant interaction between SMAD7 variants 
and use of NSAIDs two years prior to the diag-
nosis of colorectal cancer. This study also 
showed that CRC-specific survival differed 
according to the genotype of SMAD7 variants. 
Specifically, each minor allele of rs4939827 
was associated with worse survival, and each 
minor allele of rs4464148 was associated with 
better survival [19]. 
In addition to these molecular or genetic fac-
tors of tumors, the different characteristics of 
included patients and tumors could be contrib-
uting factors to the heterogeneity observed in 
the prognostic effect of NSAID use in CRC. For 
example, Coghill, et al. reported a significant 
beneficial effect of prediagnostic NSAIDs only 
in right colon cancer patients [15]. Compared 
to this study, our study included fewer right 
colon cancer patients (38.7 vs. 20.9%), sug-
gesting an explanation for the lower beneficial 
effect of NSAID use in our study.
The different stages of CRC in previous studies 
also could be an important factor related to the 
heterogeneity observed in the prognostic role 
of prediagnostic NSAID use. Most previous 
studies included all stages of CRC or the non-
advanced stages of CRC, and showed earlier 
stages at diagnosis in NSAID users than in non-
users [15], suggesting the possibility of reduced 
tumor progression and better survival due to 
NSAIDs. However, our study included only stage 
III patients to focus on the recurrence of CRC 
after adjuvant chemotherapy, and excluded the 
influence of different stages at diagnosis on 
prognosis. Even in the study that showed a ben-
eficial survival effect of prediagnostic aspirin 
use, the survival benefit was attenuated and 
disappeared after stage adjustment [15]. Our 
other data, including stage IV CRC, showed that 
long-term aspirin use before the diagnosis of 
stage IV CRC was associated with a lower 
CRCspecific survival, compared to aspirin non-
users (64.2 ± 2.5 months vs. 72.6 ± 1.0 
months; P=0.002, unpublished). 
The duration of NSAID exposure also might 
lead to different results in terms of CRC progno-
sis. Although a recent large study showed that 
the beneficial prognostic role of prediagnostic 
NSAID use is dependent on the duration of 
NSAID use, a very long-term user (>7 years) did 
not follow this duration-dependent trend [15]. 
The patients in our study had a relatively longer 
period of prediagnostic aspirin-use (average, 
61.7 months), compared with the previous 
study (average, 36 months) [19], and the 
proportion of patients with long duration (≥2 
years) of aspirin use was higher in our study 
than in another study (82.6% vs. 50%) [15]. The 
early exposure to NSAIDs during an average 
CRC carcinogenesis period of about 10 years 
and subsequently escaping this continuous 
tumor suppressive pressure for the whole 
tumor progression period might induce the 
development of different carcinogenic path-
ways, leading to different CRC characteristics 
such as resistance or poor response to adju-
vant chemotherapy. 
In this aspect, our experiments simulating the 
conditions of post-operative adjuvant chemo-
therapy in prediagnostic aspirin-exposed CRC 
(through the use of aspirin pretreatment and 
then treatment with chemotherapeutic agents 
in CRC cell lines) demonstrated that in the aspi-
rin-exposed condition for a short or long dura-
tion, the three CRC cell lines showed different 
apoptotic responses to chemotherapeutic 
agents, especially aspirin exposure duration-
dependent resistance of apoptotic response to 
a chemotherapeutic agent in Caco2 cells. There 
have been many reports about enhanced tumor 
regression with the combination of NSAIDs and 
chemotherapeutic agents [20-22]. However, as 
prolonged exposure to specific chemotherapy 
induces resistance to that agent or select che-
moresistant clones in tumor cells [23, 24], pro-
longed exposure to NSAIDs can results in the 
development of NSAID-resistant tumors in CRC 
carcinogenesis. In this aspect, for the first time, 
we showed that in some cell lines the long-term 
pretreatment of aspirin could induce the poor 
response to a chemotherapeutic agent. This 
suggests that NSAID-resistant cells could be 
an important cause of recurrence in some sub-
types of stage III CRC with long-term prediag-
nostic NSAID use. Therefore, identification of 
molecular mechanisms underlying this cell-line 
specific differential response could provide sur-
rogate markers that might indicate a favorable 
NSAID response.
Although some studies showing the beneficial 
survival effect of prediagnostic NSAID use 
explain that this benefit may be based on the 
Prediagnostic aspirin use and colorectal cancer
13444 Int J Clin Exp Med 2015;8(8):13435-13445
development of less aggressive tumors 
expressing lower level of COX-2 by NSAIDs, our 
experiments showed the possibility of the 
development of differential characteristics of 
CRCs showing poor response to a chemothera-
peutic drug through long-term exposure of aspi-
rin prior to CRC diagnosis. In the future, we 
need to elucidate the detailed molecular char-
acteristics of CRC with long-term prediagnostic 
exposure to NSAIDs.
The limitation of our study is its retrospective 
nature, including its insufficiency in record-
keeping. Therefore, a prospective cohort study 
of a large number of patients is needed to iden-
tify the effect of aspirin on the prognosis of 
stage III colorectal cancer when used over a 
certain period of time before cancer diagnosis. 
Nevertheless, this is the first study to investi-
gate a relationship between prediagnostic aspi-
rin-use and prognosis of stage III colorectal 
cancer. Its results suggest that if a particular 
tumor-suppressing agent, such as NSAIDs, is 
used for a significant duration from the initial 
tumor development, resistance might occur 
and the tumor could evade the anti-tumor 
effects of that agent, affecting tumor biology, 
the response to other anti-tumor agents, and 
the prognosis of the tumor. 
However, other factors related to NSAID 
response including the previously mentioned 
characteristics of patients, such as tumor loca-
tion, tumor genetic variants, duration of NSAID 
use, and stage, etc., should be also considered 
to interpret the effect of prediagnostic NSAID 
use on CRC survival in future studies.
In conclusion, our results show that long-term 
aspirin use before diagnosis could be a nega-
tive prognostic factor in stage III colorectal can-
cer. In order to confirm and further elucidate 
the mechanism of this, a prospective cohort 
study with a large number of patients is need-
ed. Furthermore, to identify a molecular mech-
anism and biomarker related to heterogeneity 
of the long-term prediagnostic NSAID effect on 
the tumor, molecular epidemiologic and experi-
mental studies are needed in the future. 
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